Cardiovascular adverse events associated with bispecific antibodies in relapsed or refractory B-cell non-Hodgkin lymphomas - PubMed
5 hours ago
- #lymphoma
- #pharmacovigilance
- #BsAbs
- Cardiovascular adverse events (CVAEs) are associated with bispecific antibodies (BsAbs) used for relapsed/refractory B-cell non-Hodgkin lymphomas, with 17.4% of BsAb-related reports involving CVAEs and 39.3% of those being fatal.
- Common CVAEs include shock (3.2%), bleeding (3.0%), and hypotension (2.7%), with BsAbs as a class linked to increased reporting of hypotension and fatal CVAEs compared to other drugs.
- Individual BsAbs show distinct patterns: epcoritamab has strong hypotension signals and increased fatal CVAEs, while mosunetuzumab is associated with atrial fibrillation, supraventricular tachycardia, and tachyarrhythmias.
- CVAEs occur earlier than non-CVAEs (median 10 vs. 16 days), and cytokine release syndrome overlaps in 33.4% of BsAb-related events, with hypotension commonly co-occurring, while arrhythmias often happen independently.
- Limitations like reliance on spontaneous reporting in pharmacovigilance analyses necessitate confirmation through prospective studies, highlighting the need for continued cardiovascular surveillance and risk assessment.